Bifogade filer
PDF
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Oslo, Norway, 14 April 2026 - The annual general meeting of Lytix Biopharma AS ("Lytix" or the "Company") was held today, 14 April 2026. All proposed resolutions on the agenda were approved.
In accordance with the recommendation from the Nomination and Compensation Committee, the general meeting resolved to elect the Board of Directors for a uniform term of two years. The board was reduced from seven to six members, and all board members were elected for a term until the annual general meeting in 2028.
The Board of Directors consists of the following members:
- Eric Falcand (Chair)
- Julie Dehaene-Puype
- Claus Andersson
- Darlene Deptula-Hicks
- Marie-Louise Fjällskog
- Brynjar Forbergskog
The Company would like to extend its sincere thanks to Kjetil Hestdal for his valuable contributions as a board member since 2021. His extensive experience, commitment and strategic insights have been highly appreciated and have contributed to the Company's development and progress over this period.
The general meeting also approved a new board authorization to increase the share capital in connection with the Company's option program. The authorisation replaces the previous authorization and is valid until the annual general meeting in 2028.
Minutes of the meeting are attached hereto. The minutes and all documents relevant for the annual general meeting are available on the Company's website: www.lytixbiopharma.com.
Disclosure regulation:
This information is subject to a duty of disclosure pursuant to the Company's continuing obligations as a company listed on Euronext Growth.
For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.